CompletedPhase 2NCT05509595
Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
Studying Fibrous dysplasia of bone
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Principal Investigator
- Alison M Boyce, M.D.National Institute of Dental and Craniofacial Research (NIDCR)
- Intervention
- Burosumab(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 1-99 years · All sexes
- Timeline
- 2022 – 2024
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05509595 on ClinicalTrials.govOther trials for Fibrous dysplasia of bone
Additional recruiting or active studies for the same condition.